EGFR and colorectal carcinoma: In models of HNSCC and lung cancer, patritumab enhanced radiosensitivity.[100] In CRC and NSCLC cell lines and animal models, patritumab reversed resistance to anti-EGFR treatment with cetuximab.[101, 102] In NSCLC cell lines and mouse models, patritumab also improved response to the EGFR tyrosine kinase inhibitor erlotinib.